Pandorum Technologies Secures $18 Million Series B to Advance Regenerative Therapies

Pandorum Technologies raised $18 million in a Series B funding round led by Protons Corporate, with participation from investors including Galentic Pharma and Ashish Kacholia. The biotechnology firm focuses on programmable regenerative medicine, developing exosome-based therapies targeting diseases like ocular surface disorders. The funds will support clinical development, global manufacturing expansion, and operations growth in the US, Japan, and the Middle East. Co-founder Tuhin Bhowmick emphasized advancing disease-modifying treatments through their proprietary platform.